diabetestalk.net

Effect Of Metformin On Uric Acid

Hypoglycemia And Reduced Feed Intake In Broiler Chickens Treated With Metformin

Hypoglycemia And Reduced Feed Intake In Broiler Chickens Treated With Metformin

C. M. Ashwell1 and J. P. McMurtry Growth Biology Laboratory, USDA-ARS, 10300 Baltimore Ave., Beltsville, Maryland 20705 ABSTRACT The bi-guanide metformin is used to treat noninsulin dependent diabetes in obese patients. In addi- tion to having antihyperglycemic effects, metformin is also anorectic and reduces BW. These studies were per- formed to determine if metformin possesses similar prop- erties in chickens. Metformin-HCl was administered to 14-day-old broiler chickens at either 300 or 600 mg/kg per day in the drinking water for 10 d while monitoring BW and feed intake. No changes in water intake were observed, while feed intake and daily gains were only significantly reduced by the 600 mg/kg dose. After oral administration of a single dose of 300 mg/kg metformin- HCl, feed intake was significantly reduced by 4 h and remained suppressed for greater than 24 h relative to (Key words: metformin, appetite, hypoglycemia, insulin, glucagons) 2003 Poultry Science 82:106–110 INTRODUCTION Metformin-HCl (Glucophage, Bristol-Meyers Squibb) is regarded as the first choice for therapy of type 2 diabetes that is generally characterized by insulin resistance or specifically obese patients with hyperinsulinaemia (Bray, 1999; Cusi and DeFronzo, 1998). By reducing blood glu- cose without inducing hypoglycemia and further hyper- insulinaemia, as well as reducing feed intake, metformin- HCl provides a suitable antidiabetic treatment (Lee and Morley, 1998; Rouru et al., 1992). Complications can occur with metformin-HCl induction of lactic acidosis (Stum- voll et al., 1995). High levels of fasting blood glucose, insulin resistance, and obesity are not just hallmarks of type 2 diabetes but are also normal physiologic conditions for chickens (Simon, 1989). The regulation of feed int Continue reading >>

Effect Of Diacerein As An Add-on To Metformin In Patients With Type 2 Diabetes Mellitus And Inadequate Glycemic Control

Effect Of Diacerein As An Add-on To Metformin In Patients With Type 2 Diabetes Mellitus And Inadequate Glycemic Control

Objective To evaluate the effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control. Materials and methods A randomized, double-blind, placebo-controlled clinical trial was carried out on 12 patients with T2DM and inadequate glycemic control [glycated hemoglobin A1c (A1C) ≥ 7%] with metformin as monotherapy (≥ 1500 mg per day) for at least the previous 90 days. Fasting and postprandial glucose were measured before and after the pharmacological intervention. A1C, lipid profile, creatinine and uric acid were also evaluated. After randomization, all patients continued with their dose of metformin. Six subjects received placebo and the other six volunteers took diacerein. Data were tested using the Wilcoxon signed-rank, Mann-Whitney U and chi-square tests. The Institutional Ethics Committee approved the study protocol. Results After 90 days of diacerein as an add-on to metformin, there was a significant decrease in fasting glucose (196 ± 79 vs. 149 ± 70 mg/dL, p < 0.05), postprandial glucose (262 ± 99 vs. 187 ± 70 mg/dlL, p < 0.05) and A1C (8.4 ± 2.0 vs. 6.7 ± 1.7 %, p < 0.05). Conclusions Diacerein as an add-on to metformin in patients with T2DM improved their glycemic control. Key words: Diacerein; metformin; glycemic control; type 2 diabetes mellitus Continue reading >>

Effect Of Combined Resveratrol Plus Metformin Therapy In Db/db Diabetic Mice

Effect Of Combined Resveratrol Plus Metformin Therapy In Db/db Diabetic Mice

Abstract The prevalence of Type 2 Diabetes mellitus in the world is associated with other conditions that trigger metabolic syndrome. Although there are several studies on benefits of resveratrol, few have assessed in combination of metformin. The aim of this study was to investigate at the effects of combined therapy (metformin/resveratrol) on body weight gain, biochemical clinical findings, liver and renal function of db/db diabetic mice. Diabetic mice were treated whit resveratrol (20 mg/kg/day), metformin (150 mg/kg/day) and combined therapy for 5 weeks. Histopathological tissues analyses and biochemical parameters (glucose, insulin, triglycerides and cholesterol), functional liver enzymes (AP, AST and GGT) and renal parameters (urea and uric acid) were examined. Our results clearly showed that combined therapy of resveratrol and metformin therapy reduced obesity, glucose and triglyceride levels, as well as improving renal function and partially improving liver function in diabetic mice. The combined therapy may enhance remedial effects in diabetic patients and also in other metabolic disorders as such as metabolic syndrome. Support or Funding Information CONACYT-PEI Mexico for its financial support (Project 231344). Continue reading >>

Insulin Resistance

Insulin Resistance

Insulin resistance is a condition in which the body produces insulin but does not use it properly, resulting in an excess of insulin and glucose in the blood stream. Insulin resistance increases the risk of developing prediabetes, type 2 diabetes, and cardiovascular disease (1). Metabolic syndrome consists of the co-occurrence of metabolic risk factors for type 2 diabetes and cardiovascular disease; including obesity, dyslipidemia (characterized by elevated levels of triglycerides and low levels of high-density lipoprotein cholesterol), hyperglycaemia, and hypertension. Abdominal obesity (53%), hypertension (40%), and hyperglycemia (39%) are the most frequently occurring risk factors for metabolic syndrome (2). Using criteria proposed by the National Cholesterol Education Program Adult Treatment Panel III, the 2003-2006 National Health and Nutrition Examination Survey (NHANES) data report the prevalence of metabolic syndrome in US adults greater than 20 years of age to be 34% (2). Identification of the syndrome warrants aggressive interventions known to prevent type 2 diabetes and cardiovascular disease, including weight reduction, increased physical activity, and control of hypertension and dyslipidemia. The prevalence of insulin resistance is estimated at 3% in the US (3) and will increase with the growing obesity epidemic. Endothelial dysfunction has been closely associated with obesity and insulin resistance (4). Years ago Rao et al reported that uric acid can induce vascular smooth muscle cell proliferation (5), and later the mechanism was shown to involve the uptake of uric acid via specific transporters with the activation of MAP kinases and other mediator systems (6,7). The raising of serum uric acid has also been shown to cause arteriolar disease in the kidney Continue reading >>

Have High Uric Acid ( Value= 8) Since Dec'12 , While The Fasting, Pp Values Are Under Control. Request Suggestions To Avoid Medicine

Have High Uric Acid ( Value= 8) Since Dec'12 , While The Fasting, Pp Values Are Under Control. Request Suggestions To Avoid Medicine

Have been on metformin for 8 years ( 500mg tablet after Breakfast and repeat after dinner) Started Ecospirin AV 75mg given family history of CAD Metformin is an oral diabetes medicine that helps control blood sugar levels. Metformin is for people with type 2 diabetes. Metformin is sometimes used in combination with insulin or other medications, but it is not for treating type 1 diabetes. This is a side effect of your drug which has resulted in high uric acid levels. Ask your doctor for any other alternative which is suitable as per your diabetic history . for lowering Uric Acid levels you may take chandraprabhavati tablets 3 times a days and also take Sansamani vati or Giloy Ghanvati . This will also helpful to you in lowering suger level. take sansamni vati with with cold water (Avoid refrigerator water) . Monitor your diabetes regularly. Continue reading >>

Starlix Side Effects Center

Starlix Side Effects Center

Starlix (nateglinide) is an oral diabetes medicine used together with diet and exercise to treat type 2 (non-insulin dependent) diabetes. Other diabetes medicines are sometimes used in combination with Starlix if needed. Starlix is available in generic form. Common side effects of Starlix include: weight gain, sneezing, cough, cold or flu symptoms, diarrhea, nausea, dizziness, or joint pain or stiffness. Starlix can cause low blood sugar (hypoglycemia). Tell your doctor if you have symptoms of low blood sugar such as: chills, dizziness, drowsiness, shaking, fast heartbeat, weakness, headache, tingling of the hands or feet, or hunger. Tell your doctor if you have serious side effects of Starlix including: The recommended starting and maintenance dose of Starlix, alone or in combination with metformin or a thiazolidinedione, is 120 mg three times daily before meals. Hyperglycemia (high blood sugar) may result if you take Starlix with drugs that raise blood sugar, such as: isoniazid, diuretics (water pills), steroids, phenothiazines, thyroid medicine, birth control pills and other hormones, seizure medicines, and diet pills, or medicines to treat asthma, colds or allergies. Hypoglycemia (low blood sugar) may result if you take Starlix with drugs that lower blood sugar, such as: non-steroidal anti-inflammatory drugs (NSAIDs), aspirin or other salicylates, sulfa drugs, monoamine oxidase inhibitors (MAOIs), beta-blockers, or probenecid. Tell your doctor all medications you use. During pregnancy, Starlix should be used only when prescribed. Pregnancy may cause or worsen diabetes. Discuss a plan with your doctor to manage blood sugar while pregnant. Your doctor may change diabetes treatment during your pregnancy. It is not known if this drug passes into breast milk. Consult you Continue reading >>

Gout A Painful Form Of Arthritis

Gout A Painful Form Of Arthritis

MAYO CLINIC HEALTH LETTER Gout is a form of arthritis that causes sudden, severe attacks of pain, tender- ness, redness, warmth and swelling in joints. It usually affects one joint at a time — typically the large joint of the big toe — and often at night. You may go to bed feeling fine, but then wake up in the middle of the night feeling like your big toe is on fire. The pain is so bad that you can’t even have a bed sheet covering it. Gout can also affect your ankles, knees, hands and wrists. Some people have just one attack of gout and never have another. Others have recurring attacks and may be at risk of additional problems. Medications and lifestyle changes can usually reduce or eliminate the attacks. Diet is only one factor Gout is caused by excess uric acid in the blood and tissues. Uric acid is a waste product that results from the breakdown of purines. The main source of uric acid is the breakdown of your body’s naturally occurring purines. But purines may also come from your diet. Gout was once known as the disease of kings because of its association with a diet rich in meat, seafood and alcohol — foods high in purines. However, anyone can get gout, and diet is only one factor. Why some people develop gout and others don’t is unclear, but its prevalence has been increasing over the last few decades, affecting more than 8 million Americans. The rise of conditions that often accompany gout — such as high blood pressure, obesity, diabetes, metabolic syndrome and Reliable Information for a Healthier Life Gout is a form of arthritis that causes sudden and severe attacks of pain, tenderness, redness, warmth and swelling in joints. Coming in May EYE REDNESS Beyond antibiotic eyedrops. ENDOMETRIAL CANCER Early signs can Continue reading >>

Effects Of Combined Resveratrol Plus Metformin Therapy In Db/db Diabetic Mice

Effects Of Combined Resveratrol Plus Metformin Therapy In Db/db Diabetic Mice

1CINDETEC A.C. Avenida Jurica, Industrial Park Querétaro, Querétaro, México 2Faculty of Pharmacy, Autonomous University of the State of Morelos, Cuernavaca, Morelos, México 3Nucitec, S. A. de C. V. Avenida Jurica, Industrial Park Querétaro, Querétaro, México Citation: Ángel DVM, Antonieta GSM, Rocio GC, Jorge RE, Rosado JL, et al. (2016) Effects of Combined Resveratrol Plus Metformin Therapy in db/db Diabetic Mice. J Metabolic Synd 5: 217. doi: 10.4172/2167-0943.1000217 Copyright: ©2016 Ángel DVM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Visit for more related articles at Journal of Metabolic Syndrome Abstract Background: The worldwide prevalence of Type 2 diabetes mellitus is associated with other conditions that trigger metabolic syndrome. Although several studies on the benefits of resveratrol have been carried out, few have assessed this drug in combination with metformin. Objectives: This study looks at the effects that combined metformin/resveratrol therapy has on body weight gain and liver and renal damage of db/db diabetic mice. It also addresses biochemical findings. Method: Diabetic mice were treated with resveratrol (20 mg/kg/day), metformin (150 mg/kg/day) and combined metformin/resveratrol therapy for 5 weeks. Histopathological tissue analyses and biochemical parameters (glucose, insulin, triglycerides and cholesterol), functional liver enzymes (AP, AST and GGT) and renal parameters (urea and uric acid) were examined. Results: Our data clearly showed that combined metformin/resveratrol treatment reduced obesity, glucose and triglyceride levels, as w Continue reading >>

Sglt2 Inhibitor Lowers Serum Uric Acid

Sglt2 Inhibitor Lowers Serum Uric Acid

Diabetes, SGLT2, T2 Diabetes The SGLT2 inhibitor canagliflozin is approved to treat hyperglycemia, but it may have other uses, according to a new study published in Diabetes, Obesity & Metabolism.1 “In addition to improvement in glycemic control observed in clinical trials with canagliflozin, this post-hoc analysis describes an additional potential benefit of reductions in serum uric acid levels for patients with type 2 diabetes,” commented first author Michael Davies, PhD, Scientific Director at Janssen Pharmaceuticals in Raritan New Jersey. The study found that canagliflozin could decrease serum uric acid levels by as much as 13%, compared to placebo. The study also found that up to 30% of patients with baseline hyperuricemia were able to normalize their uric acid levels after 26 weeks of taking canagliflozin. “Hyperuricaemia is associated with an increased risk of gout, kidney stones, and cardiovascular disease,” Dr Davies added. “Given the various disorders associated with hyperuricaemia, lowering serum uric acid may be beneficial for patients with type 2 diabetes, who may have a higher risk of microvascular and cardiovascular disease.” Studies have suggested that hyperuricemia could predate the development of prediabetes and diabetes.2 Hyperuricemia has also been linked to increased vascular complications and increased mortality in type 2 diabetes (T2DM).3 Dr Davies and colleagues pooled data from four phase III randomized clinical trials. Each trial lasted 26 weeks and looked at canagliflozin 100 mg or 300 mg vs placebo, either as monotherapy or as add-on to metformin alone, metformin plus a sulfonylurea, or metformin plus pioglitazone. The researchers looked at changes in serum uric acid levels in the total population of patients with T2DM (n=2313), a Continue reading >>

About This Factmed Analysis Covering Adverse Side Effect Reports Of Metformin Hydrochloride Patients Who Developed Gout.

About This Factmed Analysis Covering Adverse Side Effect Reports Of Metformin Hydrochloride Patients Who Developed Gout.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 23 individuals taking METFORMIN HYDROCHLORIDE reported GOUT to the FDA. A total of 8028 METFORMIN HYDROCHLORIDE drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication. Toxic Arthritis Food List Limit these foods to decrease arthritis pain and inflammation. naturalhealthreports.net Introduction This page is designed to help you determine the relationship, if any, between METFORMIN HYDROCHLORIDE and GOUT. In doing so, we compare METFORMIN HYDROCHLORIDE with other drugs that cause GOUT, to help you evaluate whether or not METFORMIN HYDROCHLORIDE causes GOUT. Likewise, this page shows the most highly-reported side effects of METFORMIN HYDROCHLORIDE, so you can see if GOUT ranks among METFORMIN HYDROCHLORIDE's most well-known side effects. Summary Statistics Reports of METFORMIN HYDROCHLORIDE causing GOUT: 23 Reports of any side effect of METFORMIN HYDROCHLORIDE : 8028 Percentage of METFORMIN HYDROCHLORIDE patients where GOUT is a reported side effect: 0.2865% FDA reports of any drug causing GOUT : 4844 Average percentage for all medicated patients where GOUT is reported as a complication: 0.0304% Overall opinion for all reports of this drug: In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members Continue reading >>

Physiology Of Insulin Resistance

Physiology Of Insulin Resistance

In horses, there's little doubt that high-carbohydrate feeding influences the response to insulin, but it's more complicated than in people or other animals. The horse evolved without any sources of concentrated carbohydrate in its diet. When horses are grain fed, their responsiveness to an intravenous injection of insulin drops, i.e., less insulin sensitive, more insulin resistant — yet their ability to keep blood glucose in control is usually well preserved. Insulin Resistance (IR) in ponies was reported almost 40 years ago. IR in horses was recognized less than 15 years ago. However, a 1989 USDA-sponsored survey found that 13% of the owners and equine premises surveyed reported having laminitis problems in the prior 12 months. Laminitis was second only to colic as a reason for seeking veterinary care. Prior to IR and Equine Metabolic Syndrome coming into the limelight as the "disease du jour", it was very common for breeders involved with susceptible breeds to vehemently deny they had any laminitis problems or that there was a genetic link — but insiders knew otherwise. With insulin resistance, circulating levels of insulin are elevated but glucose stays normal. The cells are resistant to insulin's signal to take up glucose, but higher levels get the job done. Horses do not progress to be frankly diabetic as easily as other species do. Diabetes mellitus is when blood sugar is higher than normal. Glucose is the most important, and the most precious, fuel in the body. Every cell needs it, even the ones that can depend heavily on fat as an energy source. The capacity to store glucose in the tissues is low. To compensate for this, many pathways exist for converting other nutrients into glucose if need be. Many amino acids can be converted to glucose. The energy crisi Continue reading >>

The Effect Of A One-year Weight Reduction Program On Serum Uric Acid In Overweight/obese Children And Adolescents.

The Effect Of A One-year Weight Reduction Program On Serum Uric Acid In Overweight/obese Children And Adolescents.

Abstract Hyperuricemia may underlie obesity and related disorders, but the impact of weight reduction and metformin on serum uric acid (sUA) in Caucasian children/adolescents is unknown.One hundred and thirteen children/adolescents were enrolled (83 completed) into 1-year weight reduction program (diet+exercise) without or with metformin. Anthropometric and biochemical measurements were conducted at baseline and at the end of follow-up (13 ± 3 months).sUA decreased in 86% females and 67% males. Significantly more patients substantially (≥ 10%) reduced their sUA than body mass index (BMI)%. In females, sUA decreased regardless of type of intervention, but more markedly in the metformin group, and ΔsUA correlated positively with ΔBMI%, ΔWHtR (waist-to-height ratio), Δinsulin, ΔHOMA (homeostasis model of assessment), and Δtriglycerides/high density lipoprotein (HDL), but correlated negatively with baseline sUA, HOMA, insulin, and triglycerides/HDL. Of these, metformin treatment, baseline sUA, and ΔBMI% were independent predictors of sUA reduction, explaining 77% of data variability. In males, sUA reduction was significant in the metformin group only, and negatively correlated with ΔWHR (waist-to-hip ratio), ΔWHtR, Δleptin, baseline sUA, and waist circumference. Of these, baseline sUA and ΔBMI% were independent predictors of sUA reduction, explaining 69% of data variability. Except for sUA, females reduced their BMI%, waist circumference, triglycerides, triglycerides/HDL and increased HDL, while males reduced total cholesterol.A longitudinal weight reduction program encompassing diet/exercise with or without metformin was more efficient in reducing sUA than weight and its effect on sUA and other metabolic parameters differed between genders. Weight loss did no Continue reading >>

Irq J Pharm Vol. Ù¡ù¡, No. Ù¢ù Ù¡ù¡ ,ù¡

Irq J Pharm Vol. Ù¡ù¡, No. Ù¢ù Ù¡ù¡ ,ù¡

Effects of glibenclamide and metformin on serum uric acid level in patients with type Ù¢ diabetes mellitus Najlaa Saadi Ismail Department of Pharmacology, Mosul College of Medicine, University of Mosul Received Accepted Ù£Ù .١١.٢٠١٠١٣.Ù§.Ù¢Ù Ù¡Ù ABSTRACT Objectives: To assess the effect of glibenclamide and metformin on serum uric acid level in patients with type Ù¢ diabetes. Study design: Case control study. Subjects and Methods: This study was conducted from March Ù¢Ù Ù Ù© to January Ù¢Ù Ù¡Ù . Fasting blood sugar and serum uric acid level were measured in patients suffering from type- Ù¢ diabetes mellitus who were referred to Al-Wafa Diabetic Center in Mosul City. Group ٣٢ :Ù¡ patients on glibenclamide therapy, group ٤٢ :Ù¢ patients on metformin therapy and group ٤٢ :Ù£ patients on combination therapy, group ٣٢ :Ù¤ patients on restricted diet, and ٢٣ apparently healthy volunteers, were taken as a control group. Results: The study showed a significant increase in the serum uric acid level of the diabetic patients as compared with the control. Glibenclamide and/or metformin showed no significant difference in the serum uric acid level in patients with type Ù¢ diabetes mellitus. Conclusion: Glibenclamide and/or metformin had no significant effect on serum uric acid level in patients with type Ù¢ diabetes mellitus. Keywords: Uric acid, hyperuricemia, type Ù¢ diabetes mellitus, glibenclamide, metformin. الخالصة Ù‰ وميتÙورمين ال عقار رتاثي لدراسة :اهدا٠البØØ« ÙŠ مصل المرضى مستوى Ø¹Ù‚Ø§Ø Continue reading >>

Use Of Metformin (siofor®) In Patients With Gout And Insulin Resistance (pilot 6-month Results)

Use Of Metformin (siofor®) In Patients With Gout And Insulin Resistance (pilot 6-month Results)

Abstract To evaluate metformin efficacy and safety in patients with gout and insulin resistance (IR). The trial included 26 patients with gout (criteria of the American collage of rheumatologists) and IR (index HOMA). The inclusion criteria were the following: absence of antigout therapy, normal hepatic and renal function, rejection of alcohol. The drug dose was 1500 mg/day. The study was made of anthropometric and clinical characteristics, 24-h blood pressure monitoring, blood tests for uric acid, glucose, insulin, urea, creatinin, alaninaminotransferase, aspartataminotransferase, lipid spectrum at the first and further visits. A 6-month metformin therapy significantly changed the levels of glucose, insulin, HDLP and LDLP cholesterol, uric acid, HOMA index. Normouricemia was achieved in 11 patients, a significant lowering of uric acid--in 12 patients. The number of affected joints in 23 patients reduced from 4 (1-5) to 1 (0-2), p < 0.01. Seven patients with achieved normouricemia had no arthritis attacks. In 3 of 10 patients with chronic arthritis joint inflammation persisted. Six patients had dyspepsia during the first week of therapy, 1 patient discontinued the drug because of persistent diarrhea. Metformin therapy is safe. It reduces IR. The principal result of the study was lowering of uric acid and attenuation of the articular syndrome. Continue reading >>

What Is It?

What Is It?

What Is It? Gout is a disorder characterized by too much uric acid in the blood and tissues. In gout, crystals of uric acid are deposited in the joints, where they cause a type of arthritis called gouty arthritis. These same crystals can also deposit in the kidneys, where they can cause kidney stones. There are three main causes of the high levels of uric acid that lead to gout: A diet rich in chemicals called purines, because purines are broken down by the body into uric acid. Foods that contain high levels of purines include anchovies; nuts; and organ foods such as liver, kidney and sweetbreads. High production of uric acid by the body. This can happen for unknown reasons. It can also occur in certain inherited genetic metabolic disorders, leukemia and during chemotherapy for cancer. The kidneys do not excrete enough uric acid. This can be caused by kidney disease, starvation and alcohol use, especially binge drinking. This also can occur in people taking medications called diuretics (such as hydrochlorothiazide or furosemide). Obesity or sudden weight gain can cause high uric acid levels because the body's tissues break down more purines. In some people, gout is caused by a combination of these factors. People with a family history of gout are more likely to develop the condition. About 90% of patients with gout are men older than 40. Gout is quite rare in younger women; when women develop gout, they are usually post-menopausal. Symptoms The first attack of gouty arthritis usually involves only one joint, most commonly the big toe. However, it can affect other joints, such as a knee, ankle, wrist, foot or finger. In gouty arthritis, the joint can become red, swollen and extremely tender to the touch. Typically, even a bed sheet brushing against the joint will trigger Continue reading >>

More in diabetes